NASDAQ Stock Threshold Pharmaceuticals Inc. (THLD) begins Thursday down slightly in Early Trading
Shares of Threshold Pharmaceuticals Inc. (NASDAQ: THLD), a Redwood City, California-based biotechnology company engaged in the discovery and development of drugs targeting the microenvironment of solid tumors as novel treatments for patients living with cancer, gets out of the gate slow in early trading today.
The small-cap stock of Threshold Pharmaceuticals ended Wednesday 7.69% higher at $3.50. In the last five trading sessions the stock gained 165.15%.
Threshold Pharmaceuticals shares have been soaring in the last few trading sessions after the company signed a global agreement with Merck KGaA of Darmstadt, Germany, to co-develop and commercialize TH-302, Threshold’s small molecule hypoxia-targeted drug.
Barry Selick, president and CEO of Threshold, said that the company is excited by the new resources that its partnership is going to bring to the development of TH-302 and the expertise in clinical development and commercialization that Merck will contribute to this program. Selick said that the collaboration provides Threshold a strong and committed partner with a shared vision for TH-302.
- This newsletter has been helping traders make a killing on THLD. Click here for a 25% discount offer.
- See today’s top stock picks and market analysis
- Need fast service and cheap rates from a broker? Buy stock online at my favorite brokerage
- Want more? Check out the message board buzz for THLD
- See what newsletters are recommending this stock pick
- Get breaking news alerts on these stocks: http://thestockmarketwatch.com/
Posted by James Mac
on Thursday, February 9th, 2012. Filed under Breaking News, Internet.
You can follow any responses to this entry through the RSS 2.0.
You can leave a response or trackback to this entry
This newsletter is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Tech24.org is a wholly-owned subsidiary of BlueWave Advisors.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
© 2012
